Eli Lilly (NYSE:LLY) Surges 5% Following Breakthrough BRAVE-AA-PEDS Study Results

Simply Wall St · 5d ago

Recent developments at Eli Lilly (NYSE:LLY) have highlighted significant strides in both product innovation and operational expansion. Among the latest announcements, the pharmaceutical giant revealed promising results from its Phase 3 BRAVE-AA-PEDS study, showcasing the efficacy of baricitinib in treating adolescents with severe alopecia areata, and the successful long-term results for EBGLYSS in managing moderate-to-severe atopic dermatitis. Furthermore, the company's decision to construct new manufacturing sites in the U.S., creating thousands of jobs, indicates an aggressive expansion strategy. Such advances likely contributed to Eli Lilly's share price increase of 5.05% over the last quarter, notwithstanding a broader market decline of 4.4% amid economic uncertainties and a slump in the tech sector. Eli Lilly's ability to thrive in a fluctuating market underscores its robust performance and continued commitment to innovation in the pharmaceutical field.

Learn about Eli Lilly's historical performance here.

NYSE:LLY Revenue & Expenses Breakdown as at Mar 2025
NYSE:LLY Revenue & Expenses Breakdown as at Mar 2025

Ready To Venture Into Other Investment Styles? Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the best rare earth metal stocks of the very few that mine this essential strategic resource.

Eli Lilly (NYSE:LLY) has delivered a very large total shareholder return of 510.70% over the past five years. Throughout this timeframe, the company has achieved significant advancements that have shaped its long-term share performance. Noteworthy moments include the emergency use authorization granted in November 2020 for bamlanivimab in treating COVID-19, which had immediate market impact. This was complemented by expanding strategic alliances, such as the November 2020 partnership with Junshi Biosciences for developing COVID-19 antibody therapies, reinforcing investor confidence in future growth prospects.

Additionally, Eli Lilly’s financial strength was highlighted by consistent earnings, including Q4 2024 results showing revenues of US$13.53 billion and net income of US$4.41 billion. Strategic decisions like the 2024 authorization of a US$15 billion share repurchase program further increased shareholder value. These elements combined underline Eli Lilly's resilience, as shown by surpassing the US Pharmaceuticals industry's return, which saw a 0.5% decline over the past year.

Already own Eli Lilly? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.